146 related articles for article (PubMed ID: 37935995)
21. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
[TBL] [Abstract][Full Text] [Related]
22. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract][Full Text] [Related]
23. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
de Feria Cardet RE; Hofman MS; Segard T; Yim J; Williams S; Francis RJ; Frydenberg M; Lawrentschuk N; Murphy DG; De Abreu Lourenco R
Eur Urol; 2021 Mar; 79(3):413-418. PubMed ID: 33341285
[TBL] [Abstract][Full Text] [Related]
24. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
25.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
26. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic accuracy of
Rajwa P; Heidenreich J; Drzezga A; Schmidt M; Shariat SF; Heidenreich A
Prostate; 2024 Jan; 84(1):74-78. PubMed ID: 37750292
[TBL] [Abstract][Full Text] [Related]
28. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
[TBL] [Abstract][Full Text] [Related]
29. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.
Bukavina L; Luckenbaugh AN; Hofman MS; Hope T; Kamran SC; Murphy DG; Yamoah K; Ost P
Eur Urol; 2023 Jun; 83(6):521-533. PubMed ID: 36404204
[TBL] [Abstract][Full Text] [Related]
30. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
31. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
Hermsen R; Wedick EBC; Vinken MJM; van Kalmthout LWM; Küsters-Vandevelde HVN; Wijers CHW; Somford DM; van Basten JA
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733
[TBL] [Abstract][Full Text] [Related]
32. Recurrence rate after radical prostatectomy following primary staging of high-risk prostate cancer with
Klingenberg S; Fredsøe J; Sørensen KD; Ulhøi BP; Borre M; Jochumsen MR; Bouchelouche K
Acta Oncol; 2022 Oct; 61(10):1289-1294. PubMed ID: 36199168
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Performance and Clinical Impact of
Cerci JJ; Fanti S; Lobato EE; Kunikowska J; Alonso O; Medina S; Novruzov F; Lengana T; Granados C; Kumar R; Rangarajan V; Al-Ibraheem A; Hourani M; Ali NS; Ahmad A; Keidar Z; Küçük O; Elboga U; Bogoni M; Paez D
J Nucl Med; 2022 Feb; 63(2):240-247. PubMed ID: 34215674
[TBL] [Abstract][Full Text] [Related]
34.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
35. Utility of Ga
Tarr GP; Kashyap P; Dixit DD; Willams AK; Koya MP; Lim R
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):78-86. PubMed ID: 31885207
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
37. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia.
Song R; Jeet V; Sharma R; Hoyle M; Parkinson B
Pharmacoeconomics; 2022 Aug; 40(8):807-821. PubMed ID: 35761117
[TBL] [Abstract][Full Text] [Related]
39. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
[TBL] [Abstract][Full Text] [Related]
40. Histopathologically Validated Diagnostic Accuracy of PSMA-PET/CT in the Primary and Secondary Staging of Prostate Cancer and the Impact of PSMA-PET/CT on Clinical Management: A Systematic Review and Meta-analysis.
Jeet V; Parkinson B; Song R; Sharma R; Hoyle M
Semin Nucl Med; 2023 Sep; 53(5):706-718. PubMed ID: 37005145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]